INmune Bio shareholders approve share increase to 6.5M; XPro shows amyloid reduction post-TBI

Inmune Bio, Inc.

Stockholders approved Amended 2021 Stock Incentive Plan, increasing shares from 4M to 6.5M; permits accelerated vesting on change of control.
XPro™ reduced Aβ42, BACE1, and caspase-3 in hippocampus; improved neurological outcomes in transgenic AD mice after TBI.
Collaboration with Virginia Commonwealth Univ. on TBI-AD link; poster presented at Keystone Symposia on June 10, 2025.
All director nominees elected; CBIZ CPAs ratified as auditor for FY2025; non-binding say-on-pay and frequency every three years approved.

item 5.02item 5.07item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.